ALX Oncology Inc.
ALX Oncology is a clinical-stage biopharmaceutical company dedicated to advancing therapies that boost the immune system to treat cancer and extend patients’ lives. They focus on developing highly differentiated medicines, including evorpacept, a novel CD47-targeted therapy, to optimize immune response and improve patient outcomes. Their mission is to deliver the next generation of breakthrough cancer therapies through compelling science and a robust pipeline.
Industries
Nr. of Employees
small (1-50)
ALX Oncology Inc.
323 Allerton Avenue, South San Francisco, CA 94080
Products
Clinical-stage CD47-blocking therapeutic candidate (lead program)
A clinical-stage CD47-targeting biologic engineered for high-affinity target binding, an inactive Fc domain to reduce off-target effects, lower molecular weight for tumor penetration, and antibody-like pharmacokinetics; being evaluated in multiple combination regimens across solid and hematologic cancers.
EGFR-targeting ADC candidate (early-phase ADC program)
An antibody-drug conjugate program in dose-escalation and expansion targeting EGFR-expressing solid tumors, currently in early-phase clinical evaluation.
Clinical-stage CD47-blocking therapeutic candidate (lead program)
A clinical-stage CD47-targeting biologic engineered for high-affinity target binding, an inactive Fc domain to reduce off-target effects, lower molecular weight for tumor penetration, and antibody-like pharmacokinetics; being evaluated in multiple combination regimens across solid and hematologic cancers.
EGFR-targeting ADC candidate (early-phase ADC program)
An antibody-drug conjugate program in dose-escalation and expansion targeting EGFR-expressing solid tumors, currently in early-phase clinical evaluation.
Services
Sponsorship and operational execution of clinical trials across multiple phases and tumor indications, including running company-sponsored trials and supplying investigational agent for partner-sponsored studies.
Conducting preclinical and clinical studies in collaboration with external partners and publishing and presenting results at scientific conferences and in peer-reviewed journals.
Sponsorship and operational execution of clinical trials across multiple phases and tumor indications, including running company-sponsored trials and supplying investigational agent for partner-sponsored studies.
Conducting preclinical and clinical studies in collaboration with external partners and publishing and presenting results at scientific conferences and in peer-reviewed journals.
Expertise Areas
- Immuno-oncology therapeutic development
- Clinical trial management (Phase 1–3)
- Translational research and biomarker development
- Regulatory strategy and IND-enabling
Key Technologies
- CD47-targeting biologics
- Monoclonal antibody combination therapies
- Antibody-drug conjugates (ADC)
- Preclinical tumor models (solid and hematologic)
News & Updates
Final analysis of the ASPEN-06 study, a phase 2/3 clinical trial evaluating evorpacept in combination with other therapies for HER2-overexpressing gastric/gastroesophageal cancer.
Results from a phase I trial of evorpacept combined with lenalidomide and rituximab in B-cell non-Hodgkin lymphoma.
A clinical trial evaluating evorpacept in combination with zanidatamab for HER2-positive and HER2-low metastatic breast cancer.
A clinical trial of evorpacept combined with enfortumab vedotin for urothelial carcinoma.
A clinical trial evaluating evorpacept with cetuximab and pembrolizumab for colorectal cancer.
A study on evorpacept alone and combined with other therapies in advanced solid tumors.
Final analysis of the ASPEN-06 study, a phase 2/3 clinical trial evaluating evorpacept in combination with other therapies for HER2-overexpressing gastric/gastroesophageal cancer.
Results from a phase I trial of evorpacept combined with lenalidomide and rituximab in B-cell non-Hodgkin lymphoma.
A clinical trial evaluating evorpacept in combination with zanidatamab for HER2-positive and HER2-low metastatic breast cancer.
A clinical trial of evorpacept combined with enfortumab vedotin for urothelial carcinoma.
A clinical trial evaluating evorpacept with cetuximab and pembrolizumab for colorectal cancer.
A study on evorpacept alone and combined with other therapies in advanced solid tumors.